Impact of discontinuation of antithrombotic therapy after surgery for chronic subdural hematoma.
Fiche publication
Date publication
août 2020
Journal
Neuro-Chirurgie
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CEBULA Hélène, Pr PROUST François
Tous les auteurs :
Todeschi J, Ferracci FX, Metayer T, Gouges B, Leroy HA, Hamdam N, Bougaci N, De Barros A, Timofeev A, Pretat PH, Bannwarth M, Roblot P, Peltier C, Lleu M, Pommier B, Chibbaro S, Proust F, Cebula H
Lien Pubmed
Résumé
The management of antithrombotic therapy (AT) after surgery for chronic subdural hematoma (cSDH) requires taking account of the balance of risk between hemorrhage recurrence (HR) and the prophylactic thromboembolic effect (TE). The goal of the present study was to evaluate the prevalence of vascular events (VE: TE and/or HR) in the first 3 postoperative months after cSDH evacuation in patients previously treated by AT. The impact of AT resumption was also evaluated.
Mots clés
Anticoagulant, Antiplatelet therapy, Antithrombotic, Chronic subdural hematoma, Thromboembolism, Vascular disorders
Référence
Neurochirurgie. 2020 08;66(4):195-202